Editorial Team: Remy Peptides Research Review Board

Who We Are

The Remy Peptides Editorial Team is the review board responsible for every research article published on this site. Our team includes pharmacology, analytical chemistry, and regulatory-analysis reviewers with expertise across the metabolic peptide pipeline.

Every article in the Research Library undergoes multi-stage review for factual accuracy, proper citation of peer-reviewed sources, and compliance with our editorial policy.

Editorial Leadership

Editorial Standards

All content follows the standards documented on the Research Standards page, including:

• Primary sourcing from peer-reviewed journals (NEJM, Lancet, Diabetes Care)
• Clinical trial data cited with ClinicalTrials.gov registration numbers
• Regulatory status verified against FDA, EMA, and MoHAP databases
• No therapeutic claims — all content framed for research context
• Regular updates when new trial readouts or regulatory decisions are published

Coverage Areas

• GLP-1 and multi-receptor agonist pharmacology
• Obesity drug approval timelines and regulatory pathways
• Peptide stability, storage, and analytical verification
• UAE regulatory compliance (MoHAP Circular 17/2022)
• Comparative efficacy data across the metabolic drug pipeline

Output

• 81 peer-reviewed research articles published
• Ongoing coverage of Phase 2/3 trial readouts and FDA advisory committees
• Regular updates to approval trackers, dosage guides, and comparison analyses